CTOs on the Move

Standards Testing Laboratory

www.stllabs.com

 
STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.stllabs.com
  • 1845 Harsh Ave SE
    Massillon, OH USA 44646
  • Phone: 330.833.8548

Executives

Name Title Contact Details

Similar Companies

Correlogic Systems

Correlogic Systems is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SIGA Technologies

SIGA Technologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aktis Oncology

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.

Eikon Therapeutics

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon`s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.